Yantai Dongcheng Biochemicals Co Ltd. Stock Analysis 002675.SZ

Yantai Dongcheng Biochemicals Co., Ltd. engages in the research, development, production and sales of heparin sodium bulk drug and chondroitin sulfate. The company is headquartered in Yantai, Shandong and currently employs 2,583 full-time employees. The company went IPO on 2012-05-25. The firm operates four segments. The Active Pharmaceutical Ingredients segment is engaged in the production and supply of heparin active pharmaceutical ingredients (API) and chondroitin sulfate. The Preparation segment is engaged in the production of lyophilized powder injections, water injections and solid preparations. The Nuclear Medicine segment is engaged in the production of radionuclide drugs, including diagnostic drugs and therapeutic drugs. The Others segment is engaged in other businesses. The firm mainly conducts businesses within the domestic market.